NCT03779087View on ClinicalTrials.gov

Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection

NACompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

July 11, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

10d TL quadruple therapy

esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.

DRUG

10d AL quadruple therapy

esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.

Trial Locations (1)

813

Kaohsiung Veterans General Hospital, Kaohsiung City

All Listed Sponsors
lead

Ping-I (William) Hsu, M.D.

OTHER

NCT03779087 - Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection | Biotech Hunter | Biotech Hunter